KBC Group

EQS-News: CANCOM SE: CANCOM publishes Annual Report 2023 and forecasts significant growth

Retrieved on: 
Wednesday, April 10, 2024
Annual report, Growth, Supervisory board, CANCOM, Internet of things, International, ERP, Economic development, Artificial intelligence, Acquisition, Bank statement, The International, KBC Group

Munich, Germany, 28 March 2024 – In the 2023 financial year, Group revenue increased by 17.8 percent to € 1,522.7 million.

Key Points: 
  • Munich, Germany, 28 March 2024 – In the 2023 financial year, Group revenue increased by 17.8 percent to € 1,522.7 million.
  • The CANCOM Group also achieved a significant increase in gross profit of 33.0 percent to € 582.3 million (prior year: € 437.9 million).
  • "Thanks to our successful acquisition strategy, we closed the 2023 financial year with significant growth," summarises Rüdiger Rath, CEO of CANCOM SE.
  • The first joint annual financial statements published with the annual report are another important milestone in the integration of the two companies.

TruEra Launches LLM Evaluation and Observability that Combines Leading Open Source Software and Massive Enterprise Scale

Retrieved on: 
Wednesday, March 13, 2024
Toxicity, UX, Organization, Software as a service, Entrepreneurship, Blog, AI, LLM, Architecture, Hallucination, KBC Group, Gen, UI, Equinix, Medical device

With these enhancements, TruEra becomes the only company with both a leading open source offering for LLM application evaluation and a scalable, enterprise-class evaluation and observability solution for both Generative and Predictive AI.

Key Points: 
  • With these enhancements, TruEra becomes the only company with both a leading open source offering for LLM application evaluation and a scalable, enterprise-class evaluation and observability solution for both Generative and Predictive AI.
  • TruEra’s open source solution, TruLens, provides LLM evaluation and tracking for the individual developer.
  • The latest release of TruEra AI Observability brings full Generative AI Observability and LLM Observability capabilities to teams, mid-size organizations, and the enterprise.
  • Learn how to get started and dive deep into the new capabilities in this blog, “ LLM Evaluation and LLM Observability - Now at Enterprise Scale .”

EQS-News: CANCOM SE: CANCOM Group grows in a difficult economic environment thanks to successful acquisition strategy

Retrieved on: 
Thursday, December 14, 2023
International, KBC Group, Growth, Federal Executive Boards, EBITDA, Acquisition, Environment, Video game

Group sales grow by 26.2 percent to €415.8 million in the third quarter (prior year: €329.5 million).

Key Points: 
  • Group sales grow by 26.2 percent to €415.8 million in the third quarter (prior year: €329.5 million).
  • Munich, Germany, 9 November 2023 – The CANCOM Group closed the third quarter with very significant growth in a challenging environment.
  • With EBITDA of €76.6 million (prior year: €80.0 million), the CANCOM Group's EBITDA margin after nine months was 7.2 percent.
  • In the International segment, the consolidation of the KBC Group quadrupled segment revenue to €151.0 million (prior year: €29.8 million).

IPA Announces Board Refreshment

Retrieved on: 
Tuesday, September 5, 2023
Health, Infectious Diseases, General Health, Research, Science, Biotechnology, IPO, Investment banking, Thrombogenicity, Therapy, KBC Group, Sustainability Accounting Standards Board, Innovation, Audit committee, Dean Witter Reynolds, Euronext Paris, Snyder, Risk, Brussels Stock Exchange, Antibody, Springer, CFO, News, Family, Ingalls, France, Annual general meeting, Management, Security (finance), IPA

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company.

Key Points: 
  • IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company.
  • The appointees will add complementary skills to the Board's skill matrix, and underline IPA’s commitment to the optimal Board composition.
  • The appointment of Messrs. Springer, Witters and Buyse and additional refreshment at the near term Annual General Meeting provides IPA’s Board with experience and expertise required for IPA to take its next steps and maximize value for shareholders."
  • Forward-looking information contained in this news release includes but is not limited to the expected results of the appointment of the three new directors to the Board, and Mr. Smith’s resignation from the Board.

Ekinops signs up for a €100 million credit line to support its external growth strategy

Retrieved on: 
Wednesday, July 19, 2023
Arrangement, Telecommunications, Policy, Carbon, CSR, Social Security Government Pension Offset, EKI, BNP Paribas, Agent, Euronext Paris, Biophysical environment, KBC Group, ESG, Social, Health, Credit, Remuneration, Bank

With a solid financial structure (€20.5 million in net cash[1] at the end of FY 2022), Ekinops has secured a new line of credit for a total €100 million, intended to provide the company with  financial resources to support its development and  in particular its external growth strategy.

Key Points: 
  • With a solid financial structure (€20.5 million in net cash[1] at the end of FY 2022), Ekinops has secured a new line of credit for a total €100 million, intended to provide the company with  financial resources to support its development and  in particular its external growth strategy.
  • These credit lines diversify Ekinops' sources of funding, extend its debt maturity, and reinforce its balance sheet in an extremely competitive market environment.
  • The trust placed in Ekinops attests to the Group's excellent financial health, and to the support of its banking partners.
  • Dmitri Pigoulevski, Ekinops' Chief Financial Officer commented:
    "This new line of financing confirms Ekinops' determination to achieve one or more acquisitions, using non-dilutive financing methods.

EQS-News: Rubean AG: New banks within the KBC Group now use Rubean's software soluti-on for payment acceptance terminals in several Central and Eastern European countries for its corporate customers

Retrieved on: 
Wednesday, February 22, 2023
CSOB, KBC Group, Integration, WKN, Fruit, ISIN, Czech Republic, Partnership, Fintech, KBC, Android, Tablet, Mobile phone, Czech

The FinTech company Rubean AG (ISIN: DE0005120802, WKN: 512080, R1B:GR) is making its payment acceptance solution available to the Czech and Slovak merchant bank CSOB and Hungarian K&H Payment Services in partnership with Global Payments Europe.

Key Points: 
  • The FinTech company Rubean AG (ISIN: DE0005120802, WKN: 512080, R1B:GR) is making its payment acceptance solution available to the Czech and Slovak merchant bank CSOB and Hungarian K&H Payment Services in partnership with Global Payments Europe.
  • These institutions are part of the Belgian financial group KBC Group NV.
  • Rubean's solution is used to receive payments on Android-controlled end devices, such as smartphones, tablets or barcode scanners.
  • "We are delighted to partner with such an innovative group as KBC," said Rubean Board Member Dr Hermann Geupel.